Opinion
Video
Author(s):
The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.
Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC
Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia
Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC
Sonrotoclax/Zanubrutinib Leads to Durable Responses in R/R CLL/SLL
2 Commerce Drive
Cranbury, NJ 08512